Phenotypic T Cell Exhaustion in a Murine Model of Bacterial Infection in the Setting of Pre-existing Malignancy
Overview
Authors
Affiliations
While much of cancer immunology research has focused on anti-tumor immunity both systemically and within the tumor microenvironment, little is known about the impact of pre-existing malignancy on pathogen-specific immune responses. Here, we sought to characterize the antigen-specific CD8+ T cell response following a bacterial infection in the setting of pre-existing pancreatic adenocarcinoma. Mice with established subcutaneous pancreatic adenocarcinomas were infected with Listeria monocytogenes, and antigen-specific CD8+ T cell responses were compared to those in control mice without cancer. While the kinetics and magnitude of antigen-specific CD8+ T cell expansion and accumulation was comparable between the cancer and non-cancer groups, bacterial antigen-specific CD8+ T cells and total CD4+ and CD8+ T cells in cancer mice exhibited increased expression of the coinhibitory receptors BTLA, PD-1, and 2B4. Furthermore, increased inhibitory receptor expression was associated with reduced IFN-γ and increased IL-2 production by bacterial antigen-specific CD8+ T cells in the cancer group. Taken together, these data suggest that cancer's immune suppressive effects are not limited to the tumor microenvironment, but that pre-existing malignancy induces phenotypic exhaustion in T cells by increasing expression of coinhibitory receptors and may impair pathogen-specific CD8+ T cell functionality and differentiation.
Sharma S, Sharma K, Kumar R, Dayal D, Dhanda S, Kumar N Pathogens. 2024; 13(6).
PMID: 38921771 PMC: 11206971. DOI: 10.3390/pathogens13060473.
Song N, Wang Z, Shi P, Cui K, Fan Y, Zeng L Oncol Lett. 2024; 28(2):354.
PMID: 38881710 PMC: 11176890. DOI: 10.3892/ol.2024.14487.
Gunes M, Rosen S, Shachar I, Gunes E Front Immunol. 2024; 15:1297473.
PMID: 38476238 PMC: 10927787. DOI: 10.3389/fimmu.2024.1297473.
SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy.
Farhangnia P, Ghomi S, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi A Front Immunol. 2023; 14:1174138.
PMID: 37251372 PMC: 10213746. DOI: 10.3389/fimmu.2023.1174138.
Vaes R, Reynders K, Sprooten J, Nevola K, Rouschop K, Vooijs M Cancers (Basel). 2021; 13(24).
PMID: 34944879 PMC: 8699057. DOI: 10.3390/cancers13246259.